Annovis Bio: Searching For Efficacy In Alzheimer’s Disease (NYSE:ANVS)

Date:


Businessman

D-Keine

On Monday, April 29th, Annovis Bio (NYSE:ANVS) announced the topline results from their phase 2/3 Alzheimer’s Disease (AD) trial. This trial was described as:

The Phase II/III study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Face the Nation: Vinograd, Becker, Buttigieg

Face the Nation: Vinograd, Becker, Buttigieg - CBS...

UN fears 670 people are dead

2 hours agoDearbail Jordan,News reporterReuters Source link